2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·24 min sittenI see that today's market value of Circio Holding is 2.2 bn. Actually a decline of nearly 38 percent from 7 april. In light of the company's development - what do we think Circio is worth today?
It is difficult to put a price tag on Circio, they have no income yet, and no assets in real estate or equipment, that is why this company is low-priced relative to its potential. Erik stated on a web, cast that their research already had a value up until today, With this, it will for now be what the buyer is willing to pay. 
·10 t sitten · MuokattuVoyager Therapeutics and Novartis are speculated in some places to be partners. Hardly. Not even the market believes in Voyager. Circio plays in a completely different league.https://www.biospace.com/business/voyager-throws-30-staff-overboard-after-novartis-sinks-two-programs Novartis is nr 8 by revenue among Big Pharma and therefore not among the big 5 as stated.
·10 t sittenWe are probably in a classic data vacuum, and there may be several reasons for that. Many had expected more data updates towards the end of Q2. The CEO has, however, been clear that the company wishes to present conclusive results rather than preliminary findings. At the same time, the share is still trading lower than many had anticipated after the capital raise, which naturally creates frustration and speculation. Concurrently, in recent months, the company has: -Raised approx. 620 MNOK with runway until at least 2030 -Strengthened the board with strong RNA and AAV expertise -Had one oral presentation and two posters accepted at ESGCT -Entered into several research collaborations where external parties are testing circVec ESGCT has a strict embargo. Full abstracts will first be made available to participants on October 13, while public communication of the content is restricted until the presentation day. Circio has stated that they will release the abstracts on October 27. This could be one contributing explanation for why certain results have not yet been communicated. However, the embargo does not automatically exempt from disclosure obligation if the data is considered material. That being said, updates could still come earlier. If the company considers the data conclusive, stock exchange announcements could be made at any time. The CFO has confirmed that an R&D webcast is planned for September 1 via email, after the half-year report on August 31. There, we should gain more insight into the progress for H2. Until then, high volatility is expected. When information is scarce, the market fills the void with speculation. It's the data that decides – not the forum.
·12 t sitten · MuokattuCircio is a much more valuable company in theory now than before the emission at 10.8. And much more valuable than before the warrant redemption. Financing risk is the biggest problem for small biotech companies. Not in Circio. One day the market will realize it. One day the dump will not come after the rise. One day the rise will continue. If you sell at the wrong time, you will have to chase it. Maybe that day comes tomorrow?
Today it will show whether this week's rise was someone's pump or if the price holds around 9.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·24 min sittenI see that today's market value of Circio Holding is 2.2 bn. Actually a decline of nearly 38 percent from 7 april. In light of the company's development - what do we think Circio is worth today?It is difficult to put a price tag on Circio, they have no income yet, and no assets in real estate or equipment, that is why this company is low-priced relative to its potential. Erik stated on a web, cast that their research already had a value up until today, With this, it will for now be what the buyer is willing to pay.
- ·10 t sitten · MuokattuVoyager Therapeutics and Novartis are speculated in some places to be partners. Hardly. Not even the market believes in Voyager. Circio plays in a completely different league.https://www.biospace.com/business/voyager-throws-30-staff-overboard-after-novartis-sinks-two-programs Novartis is nr 8 by revenue among Big Pharma and therefore not among the big 5 as stated.
- ·10 t sittenWe are probably in a classic data vacuum, and there may be several reasons for that. Many had expected more data updates towards the end of Q2. The CEO has, however, been clear that the company wishes to present conclusive results rather than preliminary findings. At the same time, the share is still trading lower than many had anticipated after the capital raise, which naturally creates frustration and speculation. Concurrently, in recent months, the company has: -Raised approx. 620 MNOK with runway until at least 2030 -Strengthened the board with strong RNA and AAV expertise -Had one oral presentation and two posters accepted at ESGCT -Entered into several research collaborations where external parties are testing circVec ESGCT has a strict embargo. Full abstracts will first be made available to participants on October 13, while public communication of the content is restricted until the presentation day. Circio has stated that they will release the abstracts on October 27. This could be one contributing explanation for why certain results have not yet been communicated. However, the embargo does not automatically exempt from disclosure obligation if the data is considered material. That being said, updates could still come earlier. If the company considers the data conclusive, stock exchange announcements could be made at any time. The CFO has confirmed that an R&D webcast is planned for September 1 via email, after the half-year report on August 31. There, we should gain more insight into the progress for H2. Until then, high volatility is expected. When information is scarce, the market fills the void with speculation. It's the data that decides – not the forum.
- ·12 t sitten · MuokattuCircio is a much more valuable company in theory now than before the emission at 10.8. And much more valuable than before the warrant redemption. Financing risk is the biggest problem for small biotech companies. Not in Circio. One day the market will realize it. One day the dump will not come after the rise. One day the rise will continue. If you sell at the wrong time, you will have to chase it. Maybe that day comes tomorrow?Today it will show whether this week's rise was someone's pump or if the price holds around 9.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·24 min sittenI see that today's market value of Circio Holding is 2.2 bn. Actually a decline of nearly 38 percent from 7 april. In light of the company's development - what do we think Circio is worth today?It is difficult to put a price tag on Circio, they have no income yet, and no assets in real estate or equipment, that is why this company is low-priced relative to its potential. Erik stated on a web, cast that their research already had a value up until today, With this, it will for now be what the buyer is willing to pay.
- ·10 t sitten · MuokattuVoyager Therapeutics and Novartis are speculated in some places to be partners. Hardly. Not even the market believes in Voyager. Circio plays in a completely different league.https://www.biospace.com/business/voyager-throws-30-staff-overboard-after-novartis-sinks-two-programs Novartis is nr 8 by revenue among Big Pharma and therefore not among the big 5 as stated.
- ·10 t sittenWe are probably in a classic data vacuum, and there may be several reasons for that. Many had expected more data updates towards the end of Q2. The CEO has, however, been clear that the company wishes to present conclusive results rather than preliminary findings. At the same time, the share is still trading lower than many had anticipated after the capital raise, which naturally creates frustration and speculation. Concurrently, in recent months, the company has: -Raised approx. 620 MNOK with runway until at least 2030 -Strengthened the board with strong RNA and AAV expertise -Had one oral presentation and two posters accepted at ESGCT -Entered into several research collaborations where external parties are testing circVec ESGCT has a strict embargo. Full abstracts will first be made available to participants on October 13, while public communication of the content is restricted until the presentation day. Circio has stated that they will release the abstracts on October 27. This could be one contributing explanation for why certain results have not yet been communicated. However, the embargo does not automatically exempt from disclosure obligation if the data is considered material. That being said, updates could still come earlier. If the company considers the data conclusive, stock exchange announcements could be made at any time. The CFO has confirmed that an R&D webcast is planned for September 1 via email, after the half-year report on August 31. There, we should gain more insight into the progress for H2. Until then, high volatility is expected. When information is scarce, the market fills the void with speculation. It's the data that decides – not the forum.
- ·12 t sitten · MuokattuCircio is a much more valuable company in theory now than before the emission at 10.8. And much more valuable than before the warrant redemption. Financing risk is the biggest problem for small biotech companies. Not in Circio. One day the market will realize it. One day the dump will not come after the rise. One day the rise will continue. If you sell at the wrong time, you will have to chase it. Maybe that day comes tomorrow?Today it will show whether this week's rise was someone's pump or if the price holds around 9.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt